CASI PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Redeemable Noncontrolling Interest
CASI PHARMACEUTICALS, INC. (CASIF) reported Net Income (Loss) Attributable to Redeemable Noncontrolling Interest of -$2.60 million for the 12-month period ending 2023-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest · last filed 2026-05-15
| Period end | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 12 month |
|---|---|
| 2023-12-31 | -$2.60M 20-F · filed 2026-05-15 |
| 2022-12-31 | -$8.74M 20-F · filed 2025-03-31 |
| 2021-12-31 | -$700.00K 20-F · filed 2024-03-28 |
| 2020-12-31 | -$918.00K 20-F · filed 2023-04-26 |